Biomedical Development Corporation is developing an effective, inexpensive, and safe sanitizer to reduce the incidence of microbial contamination in table and hatching eggs. Despite recent government initiatives to improve food safety, salmonellae contamination remains a major health concern in the United States. Phase I studies demonstrated the microbial effectiveness of the sanitizer on the surfaces of eggs and in laboratory experiments. The sanitizer was also shown to be nontoxic in safety studies and to perform favorably in tests to evaluate materials compatibility.
The aims of the Phase II Research Plan are: 1) Optimize and Characterize the Formulation; 2) Develop, Apply and Evaluate a Spray Delivery System and 3) Perform Safety Testing for Regulatory Requirements.

Proposed Commercial Applications

The monetary costs associated with salmonellosis in the United States has been estimated at 4 billion dollars annually. Salmonella contamination is one of many food safety issues that is of concern to both U.S. consumers and government regulators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AI038730-03
Application #
6169297
Study Section
Special Emphasis Panel (ZRG1-VR (01))
Project Start
1995-09-01
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2002-08-31
Support Year
3
Fiscal Year
2000
Total Cost
$190,838
Indirect Cost
Name
Biomedical Development Corporation
Department
Type
DUNS #
145377966
City
Lexington
State
TX
Country
United States
Zip Code